Biosimilars The US subsidiary of South Korea-based Celltrion Healthcare has announced that Ventegra, a major US Medical Benefits Manager (MBM) who administers pharmacy benefits through its Pharmacy Services Administration (PSA) model, will place an FDA-approved biosimilar to Roche’s Avastin (bevacizumab), Vegzelma (bevacizumab-adcd), on its commercial formulary as a preferred brand. 14 December 2023